# An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan

> **NCT06156982** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 397 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Evusheld

## Key facts

- **NCT ID:** NCT06156982
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-06
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06156982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06156982, "An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06156982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*